American Journal of Cardiology
Volume 104, Issue 4 , Pages 475-479, 15 August 2009

Relation Between Myocardial Infarct Size and Ventricular Tachyarrhythmia Among Patients With Preserved Left Ventricular Ejection Fraction Following Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction

  • Yuri B. Pride, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Evan Appelbaum, MD

      Affiliations

    • Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Erin E. Lord, BA

      Affiliations

    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Sarah Sloan, MA, MS

      Affiliations

    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Christopher P. Cannon, MD

      Affiliations

    • TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • Marc S. Sabatine, MD, MPH

      Affiliations

    • TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • C. Michael Gibson, MS, MD

      Affiliations

    • Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-525-6884; fax: 888-249-5261
  • ,
  • TIMI Study Group

Received 2 March 2009; received in revised form 6 April 2009; accepted 6 April 2009. published online 19 June 2009.

In the era of early reperfusion therapy for ST-segment elevation myocardial infarction, preserved left ventricular (LV) function is common. Despite preservation of LV ejection fraction (LVEF), there remains a spectrum of risk for adverse cardiovascular events, including ventricular tachycardia (VT) and ventricular fibrillation (VF). Larger infarct size has been independently associated with death, VT/VF, and heart failure in the post−myocardial infarction population. It was hypothesized that infarct size, as estimated by peak serum creatine kinase (CK)–MB concentration, would be associated with the incidence of VT/VF in patients with preserved LV function after ST-segment elevation myocardial infarctions. The Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In Myocardial Infarction 28 (CLARITY-TIMI 28) study enrolled 3,491 patients with ST-segment elevation myocardial infarctions who underwent fibrinolytic therapy. The association between estimated infarct size (ratio of peak CK-MB to the upper limit of normal), the LVEF (measured using left ventriculography or echocardiography), and the incidence of VT/VF through 30 days was assessed. A total of 1,436 patients underwent assessments of LV function, of whom 1,133 had adequate CK-MB for analysis. The median LVEF in this group was 55% (interquartile range 45% to 65%), and most patients (n = 814 [87.1%]) had LVEF ≥40%. Among patients with LVEF ≥40%, the ratio of peak CK-MB to the upper limit of normal was significantly associated with the incidence of VT/VF through 30 days (2.2%, 3.7%, and 5.5% across tertiles, respectively, p = 0.041 for trend) and the incidence of the composite of cardiovascular death, heart failure, shock, and VT/VF through 30 days (3.7%, 6.0%, 8.5%, respectively, p = 0.018 for trend). In conclusion, in patients with ST-segment elevation myocardial infarction with preserved LV function after reperfusion therapy, larger infarct size, as estimated by peak serum CK-MB concentration, is significantly associated with VT/VF as well as other adverse clinical outcomes.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The CLARITY-TIMI 28 study was supported by a grant from Sanofi-Aventis, Paris, France, and Bristol-Myers Squibb, Princeton, New Jersey.

PII: S0002-9149(09)00906-0

doi:10.1016/j.amjcard.2009.04.005

American Journal of Cardiology
Volume 104, Issue 4 , Pages 475-479, 15 August 2009